

Resource Summary Report

Generated by ASWG on Aug 4, 2026

NeuroNEXT

RRID:SCR_006760

Type: Tool

Proper Citation

NeuroNEXT (RRID:SCR_006760)

Resource Information

URL: http://www.ninds.nih.gov/news_and_events/proceedings/20101217-NEXT.htm

Proper Citation: NeuroNEXT (RRID:SCR_006760)

Description: THIS RESOURCE IS NO LONGER IN SERVICE. Documented on June 26, 2022. A unique clinical trial network open to studies of more than 400 neurological diseases, allowing investigators to more efficiently pursue new therapies based on scientific opportunity. The network has a centralized IRB serving 25 sites, which will allow trials to move faster, without the need to coordinate IRBs at each individual site. It is not necessary to be part of the NeuroNEXT infrastructure to propose and conduct a study within the network. The Network for Excellence in Neuroscience Clinical Trials, or NeuroNEXT, was created to conduct studies of treatments for neurological diseases through partnerships with academia, private foundations, and industry. The network is designed to expand the National Institute of Neurological Disorders and Stroke's (NINDS) capability to test promising new therapies, increase the efficiency of clinical trials before embarking on larger studies, and respond quickly as new opportunities arise to test promising treatments for people with neurological disorders. The NeuroNEXT program aims to: * Provide a robust, standardized, and accessible infrastructure to facilitate rapid development and implementation of protocols in neurological disorders affecting adult and/or pediatric populations. The network includes multiple Clinical Sites, one Clinical Coordinating Center (CCC) and one Data Coordinating Center (DCC). * Support scientifically sound, possibly biomarker-informed, Phase II clinical trials that provide data for clear go/no-go decisions. * Energize and mobilize federal, industry, foundations and patient advocacy partners by leveraging existing relationships between NINDS and NeuroNEXT to organize high impact Phase II clinical trials for neurological disorders. * Expand the pool of experienced clinical investigators and research staff who are prepared to be leaders of multicenter clinical research trials. * Working with NeuroNEXT is a cooperative venture between NINDS, the NeuroNEXT network and the applicant.

Abbreviations: NeuroNEXT

Synonyms: NeuroNEXT - Network for Excellence in Neuroscience Clinical Trials

Resource Type: knowledge environment, portal, disease-related portal, topical portal, research forum portal, data or information resource

Keywords: clinical trial, adult, pediatric, child, network

Related Condition: Neurological disorder

Funding: NINDS

Availability: THIS RESOURCE IS NO LONGER IN SERVICE

Resource Name: NeuroNEXT

Resource ID: SCR_006760

Alternate IDs: nlx_151750

Record Creation Time: 20220129T080238+0000

Record Last Update: 20260804T043314+0000

Ratings and Alerts

No rating or validation information has been found for NeuroNEXT.

No alerts have been found for NeuroNEXT.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#).

Protic D, et al. (2024) Negative effect of treatment with mGluR5 negative allosteric modulator AFQ056 on blood biomarkers in young individuals with Fragile X syndrome. SAGE open medicine, 12, 20503121241282401.

Wright KM, et al. (2023) Bioanalytical method validation and application to a phase 1, double-blind, randomized pharmacokinetic trial of a standardized Centella asiatica (L.) Urban water extract product in healthy older adults. Frontiers in pharmacology, 14, 1228030.

Berry-Kravis E, et al. (2023) Effects of AFQ056 on language learning in fragile X syndrome. The Journal of clinical investigation, 134(5).

Lowenhaupt S, et al. (2021) Virtual coordinator and site training and reorganization of a multisite consortium upon grant renewal: Challenges of the NeuroNEXT network.

Contemporary clinical trials communications, 23, 100821.

Goodman AD, et al. (2021) Response to ibudilast treatment according to progressive multiple sclerosis disease phenotype. *Annals of clinical and translational neurology*, 8(1), 111.

Brownstein MJ, et al. (2020) Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients-A Randomized Phase 2 Clinical Trial. *Journal of clinical medicine*, 9(11).

Bartlett A, et al. (2018) Recruitment & retention program for the NeuroNEXT SMA Biomarker Study: Super Babies for SMA! *Contemporary clinical trials communications*, 11, 113.

Kolb SJ, et al. (2016) Baseline results of the NeuroNEXT spinal muscular atrophy infant biomarker study. *Annals of clinical and translational neurology*, 3(2), 132.